SenzaGen receives SEK 1m follow-on order for GARD®skin Dose-Response from one of the world’s largest cosmetics companies


SenzaGen secured another project to test ingredients in cosmetics products from one of the largest cosmetics companies in the world. The new order is valued at around SEK 1 million and is for the Company’s unique in vitro test, GARD®skin Dose-Response. The testing is performed at SenzaGen’s GLP-certified laboratory in Lund, Sweden.

In July, SenzaGen received an evaluation order for GARD®skin Dose-Response from the customer, a world leader in beauty and cosmetics. The company used this test to study the dose at which a substance in a cosmetics product does not cause an allergic reaction, and it has now chosen to evaluate more substances.

“We are very pleased that the customer is satisfied with the initial evaluation phase of GARD®skin Dose-Response and is proceeding to test more ingredients. This is a crucial project with a major customer, in particular, because the test meets needs for which businesses and researchers in the cosmetics industry have sought a solution for a long time. We look forward to continuing to supply the customer with data that can help them ensure their products do not cause allergic reactions. In the second half of the year, we have seen continued strong interest from multiple companies in diverse industries, especially in our recently launched GARD®skin Dose-Response test. Existing customers are placing follow-on orders and our customer base is growing with new customers, which is very satisfying” says Peter Nählstedt, CEO of SenzaGen.

GARD®skin Dose-Response is a test based on genomic data and machine learning that provides information on the dose at which a substance causes allergy. This makes it possible for research and development to be conducted without the use of animal testing. The test enables companies in the cosmetics, pharmaceuticals and chemicals industries to identify the highest possible quantity of a chemical that they can include in their products (“the Dose of Departure”). This serves as crucial information for prioritization and decision-making in research and development. The new test is a new application domain of GARD®skin, and it is one of the first of its kind on the market.